section name header

Pronunciation

ES-moe-lol

Classifications

Therapeutic Classification: antiarrhythmics (class II)

Pharmacologic Classification: beta blockers

Indications

High Alert


Action

  • Blocks stimulation of beta1(myocardial)-adrenergic receptors. Does not usually affect beta2(pulmonary, vascular, or uterine)-receptor sites.
Therapeutic effects:
  • Decreased heart rate.
  • Decreased AV conduction.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Rapidly and widely distributed.

Metabolism/Excretion: Metabolized by enzymes in RBCs and liver.

Half-Life: 9 min.

Time/Action Profile

(antiarrhythmic effect)

ROUTEONSETPEAKDURATION
IVwithin minunknown1–20 min





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, peripheral ischemia

Derm: sweating

Endo: hypoglycemia

F and E: hyperkalemia

GI: nausea, vomiting

Local: injection site reactions

Neuro: fatigue, agitation, confusion, dizziness, drowsiness, weakness

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Brevibloc